In the bicentenary year of the Royal Victoria Hospital this review of the ulcer story will have an unashamedly Ulster bias. Although peptic ulceration was demonstrated pathologically in the 18th century the condition was rarely recognised clinically before the middle of the next century. Gastric ulceration was the commoner form at that time but by the beginning of the 20th century, duodenal ulceration had overtaken it. The incidence gradually increased until the middle of this century and was then followed by a gradual decline. It is reckoned that even now 5-10% of the population will suffer the disease at some time in their lives and 4000-5000 die annually from peptic ulcers in the British Isles as a result.
Prior to the advent of surgery the limited therapies available included bland diets, bedrest and antacids, along with many other less helpful "remedies". Although the first gastrectomy by Billroth in 1881 and the first gastroenterostomy by Wolfer the same year, were for cancer of the stomach, these operations pioneered the way for peptic ulcer surgery. Rydygier in November 1881 did the first gastrectomy for a benign ulcer with pyloric stenosis and subsequently published the report under the title "The first resection for stomach ulcer". An editor's footnote said "and I hope the last". The next few years saw the establishment of the three main operations for benign ulcers, namely gastrectomy, gastroenterostomy and pyloroplasty, all being done initially for the complications of ulceration. Vagotomy and bile vomiting together with nutritional disturbances following gastric resection for duodenal ulceration, surgeons were happy to try the new procedure of vagotomy and gastrojejunostomy or vagotomy and pyloroplasty. However, with longer follow-up recurrent ulceration occurred in 5-15% of patients following vagotomy and drainage compared to only 2-5% following gastrectomy.
Professor John Goligher, an Ulsterman working in Leeds, reported the results of a 5-8 year survey of 565 patients treated for duodenal ulcer, comparing subtotal gastrectomy, truncal vagotomy and antrectomy, truncal vagotomy and pyloroplasty and truncal vagotomy and gastrojejunostomy7. Although the trial was not randomised or followed up blindly, vagotomy and antrectomy produced the best results on Visick grading. This "belt and braces" operation, taking care of both the neural and hormonal stimulation of acid, remained popular in the USA because of a low recurrent ulceration rate of less than 2% but it carried a higher mortality than vagotomy and also gave similar post-operative problems as gastrectomy. Modifications of the vagotomy operation were introduced in the 60's. In 1957 Griffith and Harkins published their experimental data on selective vagotomy in dogs8. In this operation the hepatic branches to the liver and gallbladder and the coeliac branches to the gut are preserved. Initially it did not catch on but some claimed that it gave a more complete vagotomy because of the meticulous dissection required and that it also produced less diarrhoea than truncal vagotomy. In a randomised controlled double blind trial during 1966 and 1967, comparing truncal vagotomy and pyloroplasty with selective vagotomy and pyloroplasty in elective duodenal ulcer surgery the late Mr Terence Kennedy was able to confirm significantly less diarrhoea and also less recurrent ulceration (though not significant in) the latter operation9. However, this operation like truncal vagotomy required a drainage procedure and there were therefore still problems with dumping and bile vomiting because of the "incontinent" stomach. We then set out to compare the two drainage procedures available and in 1968 embarked on a further controlled trial comparing selective vagotomy and pyloroplasty with selective vagotomy and gastrojejunostomy10. Although there was no significant difference between the results in the two groups, there were more satisfied patients in the gastrojejunostomy group and less recurrent ulcers. In addition if dumping, diarrhoea or bile vomiting become a problem following a gastrojejunostomy it can be closed without difisculty, whereas pyloric reconstruction is a difficult and often unsuccessful procedure. It has been said that "if gastrojejunostomy is a disease then pyloroplasty is an incurable disease". Thus at this stage of our investigations we favoured selective vagotomy and gastrojejunostomy as the operation of choice. In 1969 Andrup of Copenhagan and Johnston of Leeds independently described highly selective vagotomy (also known as proximal gastric vagotomy) which left sufficient vagal innervation to the antral pump to allow gastric emptying without the necessity for a drainage procedurell12. From 1970-1972 we did a further prospective randomised trial in the Royal Victoria Hospital, comparing selective vagotomy and gastrojejunostomy with the new operation, proximal gastric vagotomy. We found that dumping and diarrhoea were virtually eliminated by the proximal gastric vagotomy but that there was a higher risk of recurrent ulceration'3. In 1990 we reported the results of 600 consecutive elective proximal gastric vagotomies for intractable duodenal ulceration with a mortality of 0.2%; one patient died in the post-operative period from cerebral haemorrhage'4.
During the 21 year period under review the overall recurrent ulceration rate was 11 %, the majority controllable by medication. Ninety-two percent of the patients were Visick grade I or II, that is satisfied patients, which compares well with the "normal" population at large where the figure is 93%. With a view to picking out patients who were more liable to recurrent ulceration following proximal gastric vagotomy, Mr John Hood looked at the pre-operative acid studies in over 260 patients who had had vagotomy'5. He found that there was a highly significant difference in the basal acid output in recurrence negative and recurrence positive patients. We therefore decided to embark on a further controlled trial on hypersecretors with basal acids above 10 mmol/l, comparing the results of proximal gastric vagotomy with truncal vagotomy and antrectomy in the special group. However, by this time the incidence of duodenal ulceration was on the decline and the numbers of hypersecretors were too small to finish the trial. In addition a further revolution overtook surgical management, namely the development of effective medical therapy.
The discovery of H2 receptor antagonists by Black in 1972 and the subsequent availability of cimetidine in 1976 followed by several similar drugs within a few years, made medical therapy attractive16. However, it soon became clear that even on maintenance therapy with these drugs, 20-25% of the patients could expect endoscopic evidence of recurrent ulceration within a year. The development of more powerful proton pump inhibitors such as omeprazole and its successors added to the phannacological armamentarium. Perhaps the biggest break through came in 1984 when Marshall demonstrated the ulcerogenic properties of a spiral flagellated bacteria, campylobacter pylori, later known as helicobacter pylori'7. Ninety per cent of duodenal ulcer patients and 70% of gastric ulcer patients were shown to be infected. Modem eradication therapy with a triple drug regime such as Omeprazole 20 mgs bid, Clarithromycin 250 mgs bid and Metronidazole 400 mgs bid for a period of one week should produce ulcer healing in 90% with only a 1% per annum chance of recurrence. However, there are still problems with patient non compliance, development of drug resistance and the onset of ulcer complications especially in the elderly on NSAID therapy in a few patients. Modem techniques allow bleeding to be controlled in most instances by endoscopic injection therapy, pyloric stenosis by balloon dilatation and perforation by laparoscopic repair. However, some patients will come to open surgery and younger surgeons now have relatively little experience of the operations required. In the past 10 years, prior to retirement, I performed, on average, only one ulcer operation per month and in my last year I operated on only 3 patients with duodenal ulceration and all were for complications.
Is this the end of the ulcer story? Undoubtedly the major role played by surgery in the past has diminished and a whole new chapter is emerging. The new villian, H pylori, is becoming better characterised, and the possibility of new nonantibiotic therapy and a vaccine against H pylori are only two of the new possible therapies being written into the script. Many twists can yet be expected before this story comes to an end.
